Drug intelligence / Profile preview

SNH-119014

Development stage: Phase 2
Lead developer: ScinnoHub Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SNH-119014 is an **oral small-molecule agonist** of **pyruvate kinase red blood cell isozyme (PKR)** developed for the treatment of **hemolytic anemias**, including but not limited to thalassemia and sickle cell disease. It acts by significantly increasing pyruvate kinase activity, raising ATP levels, and decreasing 2,3-diphosphoglycerate (2,3-DPG) in erythrocytes. The drug is being studied as a tablet formulation in Phase 1 clinical trials to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers[1][3][5][7].

Targets

PKLR (Pyruvate Kinase R)

Beyond the preview

Go deeper on SNH-119014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNH-119014.

Explore the full profile